New Low-Dose combo after transplant aims to stop leukemia relapse

NCT ID NCT06129734

First seen Apr 28, 2026 · Last updated May 16, 2026 · Updated 4 times

Summary

This study tests whether a milder chemotherapy combination (decitabine and venetoclax) given weekly after a bone marrow transplant can help prevent high-risk myeloid cancers like acute myeloid leukemia from coming back. About 20 participants will receive the treatment for up to one year, with close monitoring for side effects and relapse. The goal is to improve survival while reducing harsh side effects compared to standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University Hospitals Seidman Cancer, Case Comprehensive Cancer Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.